<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02573207</url>
  </required_header>
  <id_info>
    <org_study_id>Pending</org_study_id>
    <nct_id>NCT02573207</nct_id>
  </id_info>
  <brief_title>Recovery of Hibernating Myocardium in End Stage Heart Failure</brief_title>
  <acronym>RHIMES-HF</acronym>
  <sponsors>
    <lead_sponsor>
      <agency>Intermountain Health Care, Inc.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Intermountain Research and Medical Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Intermountain Health Care, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will collect clinical, echocardiographic, nuclear imaging and hemodynamic data in&#xD;
      a group of patients with end stage ischemic cardiomyopathy undergoing left ventricular assist&#xD;
      device (LVAD) implantation to investigate the incidence of recovery of myocardial function&#xD;
      when supported with LVADs, and to study the association between hibernating myocardium and&#xD;
      myocardial recovery in this population.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Clinical, echocardiographic and hemodynamic data will be obtained from the patients' medical&#xD;
      records. Assessment of viability will be performed using a Tl-201 Rest-Redistribution&#xD;
      Scintigraphy protocol within 2 weeks before LVAD implantation and 2 months after LVAD&#xD;
      implant. Recovery of myocardial function will be assessed using available 2D transthoracic&#xD;
      echocardiographic images and with the novel imaging modality, Speckle Tracking&#xD;
      Echocardiography (STE), in order to provide a regional quantification of the myocardium, in&#xD;
      the context of TL-201 results. Transthoracic echocardiograms will be performed 2 weeks prior&#xD;
      to the LVAD implant and 1, 2, 3, 4, 6, 9, and 12 months after implantation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    low enrollment&#xD;
  </why_stopped>
  <start_date>March 2016</start_date>
  <completion_date type="Actual">April 9, 2019</completion_date>
  <primary_completion_date type="Actual">April 9, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Recovery of Myocardial Function</measure>
    <time_frame>2 weeks prior to LVAD implant and 1, 2, 3, 4, 6, 9 and 12 months post LVAD implant</time_frame>
    <description>Recovery of myocardial function assessed continuously, using echocardiographic variables (LVEF, circumferential strain and strain rate, segmental strain and strain rate).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in the Proportion of Viable, Hibernating Myocardium and Scar after LVAD Implant</measure>
    <time_frame>2 weeks prior to LVAD implant and 2 months post LVAD implant</time_frame>
    <description>Change in the proportion of viable, hibernating myocardium and scar after LVAD implant, measured using Th-201 Rest-Redistribution Viability Study.</description>
  </secondary_outcome>
  <enrollment type="Actual">2</enrollment>
  <condition>Myocardial Function After LVAD Implant</condition>
  <condition>Ischemic Cardiomyopathy</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Adult patients (&gt;= 18 years old) with end stage ischemic cardiomyopathy receiving a LVAD at&#xD;
        the U.T.A.H. Cardiac Transplant Program. We will exclude subjects with acute forms of heart&#xD;
        failure and patients with left ventricular ejection fraction (LVEF) &lt; 40% and&#xD;
        non-obstructive coronary artery disease.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or non-pregnant female &gt;= 18 years of age.&#xD;
&#xD;
          2. End stage chronic and dilated ischemic cardiomyopathy requiring LVAD support.&#xD;
&#xD;
          3. Ability to understand and sign a written informed consent form, which must be obtained&#xD;
             prior to initiation of any study procedures.&#xD;
&#xD;
        Ischemic cardiomyopathy is defined by a LVEF &lt; 40% and any of the following:&#xD;
&#xD;
          -  History of myocardial infarction or revascularization.&#xD;
&#xD;
          -  History of angina or chest pain and evidence of scarring in non-invasive imaging&#xD;
             studies corresponding to previous myocardial infarction.&#xD;
&#xD;
          -  Presence of ≥ 75% stenosis of the left main or proximal left anterior descending&#xD;
             artery, or ≥ 75% stenosis of 2 or more epicardial vessels in a patient with&#xD;
             unexplained cardiomyopathy.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant and/or lactating women and women of child bearing potential who are not using&#xD;
             acceptable means of contraception. Women of childbearing potential must be using&#xD;
             adequate measures of contraception (as determined by the Investigator) to avoid&#xD;
             pregnancy and should be highly unlikely to conceive during the study period. Women of&#xD;
             childbearing potential must have a negative pregnancy test at screen.&#xD;
&#xD;
          -  Patients with acute forms of HF: acute onset of symptoms &lt; 3 months, no left and right&#xD;
             ventricular dilation.&#xD;
&#xD;
          -  Other conditions that in the opinion of the Principal Investigator may increase risk&#xD;
             to the subject and/or compromise the quality of the clinical trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Abdallah G Kfoury, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Intermountain Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Intermountain Heart Institute</name>
      <address>
        <city>Murray</city>
        <state>Utah</state>
        <zip>84143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>October 7, 2015</study_first_submitted>
  <study_first_submitted_qc>October 7, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 9, 2015</study_first_posted>
  <last_update_submitted>April 1, 2021</last_update_submitted>
  <last_update_submitted_qc>April 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiomyopathies</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

